Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.

被引：0

作者：

Gilbert, Lucy

Oaknin, Ana

Matulonis, Ursula A.

Mantia-Smaldone, Gina

Lim, Peter C.

Castro, Cesar Martin

Provencher, Diane M.

Memarzadeh, Sanaz

Wang, Jiuzhou

Esteves, Brooke

Zweidler-McKay, Patrick A.

Moore, Kathleen N.

O'Malley, David M.

机构：

[1] McGill Univ, Royal Victoria Hosp, Hlth Ctr, Montreal, PQ, Canada

[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[5] Renown Reg Med Ctr, Ctr Hope, Reno, NE USA

[6] Harvard Med Sch, Massachusetts Gen Hosp, Reading, MA USA

[7] Univ Montreal, Montreal, PQ, Canada

[8] Univ Calif Los Angeles, Los Angeles, CA USA

[9] ImmunoGen Inc, Waltham, MA USA

[10] Kadmon Rsrch Inst, Wilmington, MA USA

[11] ImmunoGen, Waltham, MA USA

[12] Univ Oklahoma, Med Ctr, Oklahoma City, OK USA

[13] Ohio State Univ, Coll Med, Columbus, OH 43210 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6004

引用

页数：2